Transitioning HCP Engagement with QBlast™ and QPharmaRx™
Download The Background A Top 20 pharmaceutical company decided to eliminate its entire salesforce, impacting how they interacted with their healthcare providers (HCPs). The company needed to communicate this change effectively to their target HCPs and provide them with an alternative way to request samples, literature, and other promotional items through the QPharmaRx HCP portal. […]
Enhancing eLearning with AI Narration: Scalable, High-Quality Training for Modern Learners
As eLearning evolves, organizations need faster, more flexible ways to create training without compromising quality. AI-powered narration has emerged as a practical solution, enabling teams to produce clear, consistent voiceovers efficiently while keeping pace with changing business needs.
CMS Open Payments Review Period – Managing Disputes and Late Submissions
Each year, the CMS Open Payments review and dispute period, April 1st through May 15th, places pressure on pharmaceutical manufacturers to validate data accuracy, resolve disputes, and submit corrections under tight deadlines. Late submissions, corrections or unresolved disputes can increase compliance risk, invite regulatory scrutiny, and damage stakeholder trust, particularly as expectations around aggregate spend and transparency reporting continue to rise.
When Poor Vendor Performance Becomes a Business Risk: Why It May Be Time to Make a Change
Pharmaceutical companies rely on a wide network of external vendors to support critical functions across commercial, regulatory, and operational areas. These partners often operate behind the scenes, but their performance has a direct impact on compliance, efficiency, and reputation. When a vendor relationship is working well, it blends seamlessly into daily operations. When it is not, the effects are felt quickly and broadly.
Sales Representative Registration Isn’t Optional: What Miami-Dade Teaches Pharma About Lobbyist Compliance
Imagine losing access to a major Southeast public health system because your field representatives weren’t properly registered. For pharmaceutical manufacturers, that risk is very real in jurisdictions like Miami‑Dade County, where strict, actively enforced rules govern who can engage with public institutions.
How Digital Sampling Is Transforming HCP Engagement at Medical Congresses
Medical congresses create powerful moments of HCP interest, but too often, that momentum is lost. Explore how digital sampling is closing the gap between engagement and action through a compliant, next-generation experience.
From Insight to Impact, Part 2: Preparing for a Powerful Conference Season
The value you gain from a conference is determined long before the first keynote session begins. With the right preparation, a conference becomes more than an event, it becomes a strategic accelerator for your growth, your team, and your organization.
Validation Documentation Is Just Like Baseball, Right?
When viewed in comparison to baseball, validation becomes not just a compliance requirement, but a strategic advantage grounded in preparation and precision.
Where Big Pharma Consumer Marketing Is Headed in 2026 and Beyond
As Big Pharma accelerates into 2026 and beyond, one truth is clear: the future of consumer marketing will belong to organizations that pair innovation with operational excellence and rock solid compliance.
Transitioning HCP Engagement with QPharma®
QPharma Drives Digital Innovation in HCP Engagement at Psych Congress
